Nexavar Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals, Inc. - Treatment for Advanced Renal Cell Carcinoma

Nexavar is an oral multi-kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer.

Posted: December 2005

Related Articles:

Nexavar (sorafenib) FDA Approval History

View comments

Hide
(web3)